Suchergebnisse - "Tamura, Tomohide"

PubPharm (62)

1

Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer

enthalten in: Cancer science | 2020

von Kanda, S. | Ohe, Y. | Goto, Y. | +6

2

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

enthalten in: Investigational new drugs | 2019

von Nishio, M. | Murakami, H. | Ohe, Y. | +11

3

Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Udagawa, H. | Akamatsu, H. | Tanaka, K. | +13

4

Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non-Small-Cell Lung Cancer

enthalten in: Clinical lung cancer | 2019

von Nokihara, H. | Nishio, M. | Yamamoto, N. | +10

5

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer : A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2019

von Watanabe, S. | Yoshioka, H. | Sakai, H. | +19

ErratumIn: Lung Cancer. 2019 Jun;132:157-158. - PMID 31014853

6

Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors : a phase 1 study

enthalten in: Investigational new drugs | 2018

von Fujiwara, Y. | Yamazaki, N. | Kiyohara, Y. | +8

7

Three-Year Follow-Up of an Alectinib Phase I/II Study in ALK-Positive Non-Small-Cell Lung Cancer : AF-001JP

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Tamura, T. | Kiura, K. | Seto, T. | +14

8

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors

enthalten in: Investigational new drugs | 2017

von Yamamoto, N. | Nokihara, H. | Yamada, Y. | +7

9

Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy

enthalten in: Investigational new drugs | 2017

von Tambo, Y. | Hosomi, Y. | Sakai, H. | +15

10

A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors

enthalten in: Japanese journal of clinical oncology | 2017

von Nokihara, H. | Yamamoto, N. | Yamada, Y. | +8

1
2
3
4
5
6
7
Nächster »
[7]